Testing services for the development of IMP9064 will be provided by Burning Rock in both the US and China in collaboration with IMPACT Therapeutics
FREMONT, CA: Tests aid in the diagnosis and staging of cancer, as well as in determining therapy options and monitoring response to treatment. They also help determine therapy response and prognosis. Burning Rock Biotech Limited has collaborated with IMPACT Therapeutics, where Burning Rock will be providing testing services in connection with IMPACT Therapeutics' development of its ATR inhibitor IMP9064, which has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for the Phase I/II clinical study and will begin soon in the US. Burning Rocks CLIA and CAP-approved laboratories in Guangzhou, China, and California, USA, will support the partnership.
IMPACT Therapeutics discovered and developed the ATR inhibitor IMP9064, which has worldwide intellectual property rights. ATR inhibitor IMP9064 was found to be highly effective in preclinical investigations and to be selective for ATR kinase. As a result, IMP9064 has exhibited strong activity in ATM-deficient cell lines and xenograft in vivo models, which could lead to a broader therapeutic window, better tolerability in long-term treatment as a single agent, and greater flexibility in combination therapy. Clinical trials for IMPACT Therapeutics' PARP inhibitor Senaparib have taken place around the world. Combining an ATR inhibitor and a PARP inhibitor is highly anticipated in DNA Damage Response (DDR) research.
CAP and CLIA certificates have been awarded to Burning Rock's labs in Guangzhou, China, and California, respectively, and both laboratories have been inspected and certified (CMS). Certified laboratories have also assisted IMPACT Therapeutics' global strategic partnership in CDx development for a pipeline of deadly synthetic pharmaceuticals, including Senaparib'sCDx development.